Preservica
30.1.2024 15:12:31 CET | ACCESS Newswire | Press release
GSK Selects Preservica Enterprise for its Corporate Archive, Ushering in a New Era of Digital Asset Resilience and Accessibility in Pharmaceuticals
BOSTON, MA and OXFORD, UK / ACCESSWIRE / January 30, 2024 / Preservica, a global leader in Active Digital Preservation™ archiving, is thrilled to announce GSK (GlaxoSmithKline), a multinational pharmaceutical and biotechnology company, has officially chosen Preservica as its Digital Preservation and archiving supplier for their Corporate Heritage Archives.
As a global leader in uniting science, technology and talent, GSK opted for Preservica's Enterprise edition with Active Digital Preservation™, ensuring not only the secure storage of historical records but also the continuous management, accessibility and protection of critical corporate governance and compliance documents in a way that goes beyond conventional archiving solutions.
The choice of Digital Preservation reflects a strategic decision to ensure the accessibility, integrity and longevity of these records. By leveraging Preservica, GSK not only fulfills its archival needs but also establishes a foundation to inform and protect the future of the business, offering valuable insights for strategic decision-making and ensuring a robust framework for regulatory compliance and brand continuity.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.GSK employee working in tuberculosis imaging laboratory at Tres Cantos site, Madrid
"After a comprehensive evaluation of preservation solutions, we confidently selected Preservica," said Jill Moretto, Senior Information Governance and Heritage Archive Manager. "Preservica automates our content migration workflows and also integrates seamlessly with our collections management system, Qi. Overall, it's simplifying our processes and eliminating duplicative work for the GSK Heritage team. This streamlined workflow is instrumental in documenting our contributions and legacy in health, science, industry, culture and the community, showcasing our impact on a global scale. Preservica completes GSK Heritage's core needs as a corporate archive. I'm so excited to use it to protect our legacy as we continue to get ahead of disease together."
Preservica Enterprise solution seamlessly integrates all essential elements for successful Digital Preservation, including public and secure access. The Enterprise edition not only meets but exceeds core requirements, offering a singular, integrated application that delivers comprehensive, scalable and fully compliant protection for critical long-term assets.
"This partnership stands as a testament to Preservica's commitment to advancing digital preservation standards across industries," said Preservica CEO, Mike Quinn. "Preservica is proud to contribute to the resilience and longevity of digital assets in an arena where historical data integrity directly influences advancements in healthcare and pharmaceutical breakthroughs."
The collaboration focuses on bolstering internal and external communications, as well as supporting marketing initiatives through the preservation of diverse file formats, including AV, TIFF, JPEG and standard office formats.
For more information on how Preservica is part of an international community of pharmaceutical institutions worldwide that are choosing Preservica as their trusted partner for Digital Preservation, visit preservica.com.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at gsk.com.
About Preservica
Preservica is transforming the way organizations around the world protect and future-proof critical long-term digital information. Available in the cloud (SaaS) or on-premise, our award-winning Active Digital Preservation™ archiving software has been designed from the ground up to tackle the unique challenges of ensuring digital information remains accessible and trustworthy over decades.
It's a proven solution that's trusted by thousands of businesses, archives, libraries, museums and government organizations around the world, including the UK National Archives, Texas State Library and Archives, MoMA, Yale and HSBC.
preservica.com
Twitter: @Preservica
LinkedIn: @Preservica
Media Contact:
Aleeza Goodman
York IE
aleeza@york.ie
SOURCE: Preservica
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans30.9.2026 15:50:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally. Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match. The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata
Clean Air Metals Files Interim Financial Statements for the Six Months Ended July 31, 202630.9.2026 00:45:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / September 29, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the six-month period ended July 31, 2026, available for viewing on www.sedarplus.ca. Financial HighlightsTotal assets as at July 31, 2026 of $35,465,204Total cash as at July 31, 2026 of $422,500Working capital deficiency as at July 31, 2026 of $3,188,114Shareholder's equity as at July 31, 2026 of $31,803,864 During the six-month period ended July 31, 2026, the Company incurred $164,309 in cost for exploration activities at the Thunder Bay North project. During the second fiscal quarter, the Company focused on finalizing the proposed amalgamation while continuing discussions on Advanced Exploration permitting and re-assessment of past geophysical work to highlight areas of focus for drilling and geophysics in
Continent 8 and FuturePath AI Launch Future8: Accountable AI for Regulated Industries29.9.2026 15:00:00 CEST | Press release
LISBON, PT / ACCESS Newswire / September 29, 2026 / Continent 8 Technologies and FuturePath AI today launched Future8, an AI-native operating company built for regulated operators, formed as a joint venture between the two companies. Announced at SBC Summit Lisbon, Future8 combines FuturePath's enterprise AI applications platform with Continent 8's licensed global operating footprint, enabling the iGaming industry to deploy auditable AI without compromising compliance, data sovereignty and operational control. Built for highly regulated environments, Future8 enables operators to move from AI experimentation to production deployment by embedding governance, approvals and auditability into every workflow from day one. Continent 8 brings licensed data centers and a private global network spanning more than 100 locations, built over 28 years serving the biggest iGaming and online brands, along with AI-enabled Global Capability Centers in India, the Philippines and Bulgaria. The company als
Europe SPAC Summit 2026 Invites European Private Companies to Explore the SPAC Path to U.S. Public Markets29.9.2026 15:00:00 CEST | Press release
NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / A growing number of European companies in frontier technologies, critical minerals, advanced manufacturing, defense tech, energy, and consumer sectors are evaluating a merger with a special purpose acquisition company (SPAC) as a faster route to a U.S. listing, a valuation that reflects global investor demand, and access to follow-on capital. The Europe SPAC Summit 2026 (ESPAC'26), co-hosted by AUM Advisors and MBP Global, is inviting the CEOs, CFOs, founders, and board members of late-stage European private companies to The Dolder Grand in Zurich on Thursday, December 10, 2026, to learn how the process works and to meet the investment bankers, institutional investors, and SPAC sponsors who make these transactions happen. Attendance is by invitation only and free of charge for qualified companies. Europe's recent de-SPACs show what is possible. Kyivstar, Ukraine's largest mobile operator, listed on Nasdaq thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom